Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

The Belgian government is pushing forward with efforts to get rid of the anonymity of sperm donors after it transpired that a ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

For decades, gynecologic cancer treatment has used aggressive surgical intervention and chemotherapy. These methods often ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Research on cancer metastasis uncovers genetic complexities, showing that copy-number alterations play a key role in tumor ...

Prime editing is an advanced gene editing technology that enables precise DNA corrections without introducing double-stranded breaks, significantly reducing off-target effects. This innovation holds ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...